Extended Ceftiofur Therapy for Treatment of Experimentally-Induced Streptococcus uberis Mastitis in Lactating Dairy Cattle

From: Journal of Dairy Science | Date: October 1, 2004| Author: Almeida, R A; Et al; Gillespie, B E; Headrick, S J; Oliver, S P | Copyright information

ABSTRACT

Streptococcus uberis is an important cause of mastitis in dairy cows throughout the world, particularly during the dry period, the period around calving, and during early lactation. Strategies for controlling Strep. uberis mastitis are poorly defined and are currently inadequate. Objectives of the present study were to evaluate efficacy of ceftiofur, a new broad-spectrum cephalosporin antibiotic, for treatment of experimentally induced Strep. uberis intramammary infect...

Read all of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and journal articles from HighBeam Research

Extended Ceftiofur Therapy for Treatment of Experimentally-Induced Streptococcus uberis Mastitis in Lactating Dairy Cattle
Journal of Dairy Science ; ABSTRACT Streptococcus uberis is an important cause of mastitis in dairy cows throughout the world, particularly during the dry period, the period around calving, and during early lactation. Strategies for controlling Strep. uberis mastitis are poorly defined and are currently inadequate.
Efficacy of Extended Ceftiofur Intramammary Therapy for Treatment of Subclinical Mastitis in Lactating Dairy Cows
Journal of Dairy Science ; ABSTRACT Little research has focused on treatment of cows with subclinical mastitis during lactation. Ceftiofur is a new broad-spectrum, third-generation cephalosporin antibiotic for veterinary use that inhibits bacterial cell wall synthesis by interfering with enzymes essential for peptidoglycan
Compliance is the issue.
Dermatology Nursing ; How many times have you had a patient return for followup and find out that the treatment prescribed is not working? Generally the treatment is adjusted and the patient sent home only to return again with another treatment failure. Do you ever stop to think why the treatments continue to be
Quiz: WOUND CARE
DVM ; Test your acumen with trauma from the field The following hOrSeS are actual clinical cases seen by our experts and by equine practitioners in the field. Using the main points and topics of concern that have been addressed throughout this series on wound management, and using your own practice
Factors Affecting Cure and Somatic Cell Count After Pirlimycin Treatment of Subclinical Mastitis in Lactating Cows
Journal of Dairy Science ; ABSTRACT This study investigated the associations of both bacteriological cure and quarter somatic cell count (SCC) after intramammary antibiotic treatment with treatment duration, cow characteristics, and pretreatment bacteriology and SCC. For the purpose of this paper, data from 2 treatment
Levaquin dose.(RXs)(Ortho-McNeil Pharmaceutical Inc.)(Brief Article)
Chain Drug Review ; The Food and Drug Administration has approved a five-day treatment regimen for Levaquin among patients with mild-to-severe community-acquired pneumonia. The injection is marketed by Ortho-McNeil Pharmaceutical Inc.
Ethocyn Selects 1996-1997 "Half-Face" Spokesperson
Italian Voice, The ; Alfred Weiss Italian Voice, The 10-17-1996 Ethocyn Selects 1996-1997 "Half-Face" Spokesperson. Have you seen the Chantal Skin Care Ethocyn "Seeing is Believing" ads and commercials? Karen Phillips, the 1995-1996 "Half-Face" spokesperson, followed Chantal's Ethocyn Skin Treatment Regimen on only
Ambulatory nursing outcomes
AAACN Viewpoint ; AAACN Participates in Classification Study on Patient Outcomes During 2000, AAACN participated in a research study conducted by the Nursing Outcomes Classification (NOC) research team at the Center for Nursing Classification, College of Nursing, The University of Iowa. The classification center has
The challenge of normalization for families of children with chronic conditions. (Family Matters).(Abstract)
Pediatric Nursing ; The concept of normalization continues to be of interest to both clinicians and researchers. Studies of families facing diverse illness challenges consistently have found that over time family members come to view both the child and their life as normal. For example, Homer (1998) described families
Seborrheic dermatitis regimen.(Products)
Skin & Allergy News ; Xolegel Duo is a new combination treatment regimen for seborrheic dermatitis of the scalp, face, and body. Xolegel Duo consists of a gel for the skin, Xolegel (ketoconazole 2%, USP), and a shampoo for the scalp, called Xolex (zinc pyrithione 1 The two products are made by Barrier Therapeutics. For